Piramal Group
Piramal Group is an Indian multinational conglomerate with businesses spanning financial services, pharmaceuticals, healthcare, life sciences, real estate and philanthropy.
Last updated October 14, 2026
AI crawler reads
No AI crawler has read this profile since Oct 28, 2026.
Overview
Piramal Group is an Indian diversified business group headquartered in Mumbai. Under the leadership of Ajay Piramal, it evolved from a textile-centered family enterprise into a multinational group whose principal activities are financial services, pharmaceuticals and healthcare, real estate, and social-impact initiatives. The group’s modern history began in 1984, when Ajay Piramal acquired Gujarat Glass Limited, a manufacturer of glass packaging used by pharmaceutical and cosmetics companies. This transaction marked the start of a diversification strategy away from the group’s earlier textile interests, which were associated with Morarjee Mills. The group entered healthcare in 1988 by acquiring the Indian operations of Nicholas Laboratories. It subsequently expanded through acquisitions and operating investments, including Roche Products (India) in 1993, a controlling stake in Sri Lanka’s Ceylon Glass Company in 1999, and a Pfizer manufacturing plant in Morpeth, England, acquired by its UK subsidiary in 2006. During the 2000s, the healthcare businesses developed research and commercial relationships with international pharmaceutical companies including Merck and Eli Lilly. A major strategic turning point came in 2010, when the group sold its domestic formulations business to Abbott Laboratories for approximately US$3.72 billion. The transaction generated capital for further expansion while leaving Piramal with other healthcare, analytics and industrial interests. Piramal Diagnostic Services was also sold to Super Religare Laboratories in the same year. In 2012, Piramal Healthcare was renamed Piramal Enterprises, reflecting a broader corporate identity and a strategic shift toward financial services alongside specialty healthcare. Piramal Enterprises acquired Decision Resources Group, a healthcare analytics company, and later integrated the UK-based Abacus International business. The group also entered or expanded in lending, real-estate finance, corporate finance and distressed-asset investing. Financial services became increasingly central during the 2010s. Piramal held an 11% stake in Vodafone India between 2011 and 2014 and developed platforms for corporate and real-estate lending. Its alternatives business formed the India Resurgence Fund with Bain Capital Credit in 2016 to invest in financially distressed Indian companies. A separate Piramal Capital Fund partnership with CDPQ began in 2020. The group also continued to operate in pharmaceuticals and medical products, receiving a European CE mark for BST-CarGel in 2012 and supporting the development of the radiopharmaceutical NeuraCeq. The group’s industrial portfolio was further reshaped in 2020, when its glass-packaging business was sold to The Blackstone Group for approximately US$1 billion. In financial services, Piramal Capital & Housing Finance acquired Dewan Housing Finance Corporation in 2021 through India’s insolvency-resolution framework. The transaction was described as the first resolution of a financial services company under the Insolvency and Bankruptcy Code. Piramal’s pharmaceutical activities were demerged into Piramal Pharma Limited in 2022, creating a separately listed pharmaceutical and life-sciences company. In September 2025, Piramal Enterprises merged into its subsidiary Piramal Finance Limited. The restructuring responded to Reserve Bank of India requirements for systemically important upper-layer non-banking financial companies to be publicly listed. The combined business, focused on retail and wholesale lending, began trading on the National Stock Exchange and Bombay Stock Exchange under the ticker PIRAMALFIN on 7 November 2025. As described in the supplied reference material, Ajay Piramal remains group chair, while Anand Piramal chairs Piramal Finance. The group’s principal operating pillars are now Piramal Finance, Piramal Pharma and Piramal Realty, complemented by the Piramal Foundation’s programs in health, education, water access, liveli…
History
Piramal Group traces its origins to a family business with textile interests, including Morarjee Mills. After the 1982 Bombay textile strike and the deaths of his father Gopikishan and brother Ashok, Ajay Piramal led the group toward diversification. The first defining step was the 1984 acquisition of Gujarat Glass Limited, which supplied glass packaging to pharmaceutical and cosmetics companies. This move gave the group an industrial platform adjacent to healthcare and laid the foundation for its later pharmaceutical expansion. In 1988, the group entered healthcare by purchasing the Indian operations of Nicholas Laboratories. It added Roche Products (India) in 1993, including a vitamin-A manufacturing facility in Thane, and acquired a controlling interest in Sri Lanka’s Ceylon Glass Company in 1999. The group’s international manufacturing footprint expanded in 2006, when its UK subsidiary bought a Pfizer manufacturing plant in Morpeth, England. During this period, Piramal developed research relationships with companies such as Merck and Eli Lilly and built capabilities in pharmaceuticals, contract manufacturing and healthcare products. The group made a decisive portfolio move in 2010 by selling its domestic formulations business to Abbott Laboratories for approximately US$3.72 billion. It also sold Piramal Diagnostic Services to Super Religare Laboratories. The transactions reduced the group’s exposure to domestic branded formulations and released capital for new sectors. Piramal Healthcare was renamed Piramal Enterprises in 2012, reflecting the company’s expansion beyond its original healthcare identity. The next phase combined specialty healthcare with financial services and analytics. In 2012, Piramal acquired Decision Resources Group, a healthcare analytics company, and subsequently integrated Abacus International. The group also pursued lending activities focused on real estate and corporate borrowers. It held an 11% stake in Vodafone India from 2011 to 2014. In healthcare, it received a European CE mark for BST-CarGel in 2012, while the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive recommendation for NeuraCeq in 2013. Piramal also acquired the Caladryl brand in India from Valeant Pharmaceuticals in 2013. Financial services increasingly became a central growth engine. Piramal Enterprises and Bain Capital Credit established the India Resurgence Fund in 2016 to invest in financially distressed Indian businesses. A partnership with CDPQ created the Piramal Capital Fund in 2020, and Piramal Alternatives was established to manage these and related investment activities. In the same year, Piramal sold its glass-packaging business to The Blackstone Group for approximately US$1 billion, completing the disposal of a business that had been central to the group’s early diversification. In 2021, Piramal Capital & Housing Finance acquired Dewan Housing Finance Corporation through the insolvency process for a reported consideration of ₹34,250 crore. The transaction was significant because it represented the first resolution of a financial-services company under India’s Insolvency and Bankruptcy Code. Piramal’s healthcare and pharmaceutical operations were reorganized in 2022, when Piramal Pharma Limited was demerged and separately listed. Its businesses include Piramal Pharma Solutions, Piramal Critical Care and the Piramal Consumer Products Division, as well as interests in specialty pharmaceutical and ophthalmology products. The group’s latest structural change was completed in September 2025, when Piramal Enterprises merged into its subsidiary Piramal Finance Limited. The transaction addressed regulatory requirements for publicly listing upper-layer non-banking financial companies by September 2025. The resulting listed entity focuses on retail and wholesale lending, including housing, vehicle, corporate and real-estate finance. It began trading under PIRAMALFIN on 7 November 2025. Alongside Piramal Finance and Piramal Pharma, Piramal Realty remains the group’s real-estate platform, while the Piramal Foundation operates social programs in health, education, clean water and livelihoods.
- 2025
Piramal Enterprises merges into Piramal Finance
[1]The reverse merger created Piramal Finance as the group’s primary listed financial-services arm.
- 2025
PIRAMALFIN listing
[1]The merged financial-services entity began trading on Indian exchanges under the ticker PIRAMALFIN on 7 November 2025.
- 2022
Piramal Pharma demerger
[1]The pharmaceutical division was separated from Piramal Enterprises and listed as Piramal Pharma Limited.
- 2021
DHFL acquisition
[1]Piramal Capital & Housing Finance acquired Dewan Housing Finance Corporation through India’s insolvency-resolution framework.
- 2020
Glass business divestment
[1]The group sold its glass-packaging business to The Blackstone Group.
- 2016
India Resurgence Fund established
[1]Piramal and Bain Capital Credit created India Resurgence Fund to invest in distressed Indian companies.
- 2012
Piramal Healthcare becomes Piramal Enterprises
[1]The company adopted the Piramal Enterprises name as it broadened its activities into financial services and healthcare analytics.
- 2012
Decision Resources Group acquisition
[1]Piramal acquired healthcare analytics company Decision Resources Group and later integrated Abacus International.
- 2010
Abbott formulations transaction
[1]Piramal sold its domestic formulations business to Abbott Laboratories and also divested Piramal Diagnostic Services.
- 2006
Morpeth manufacturing acquisition
[1]Piramal’s UK subsidiary acquired a Pfizer manufacturing plant in Morpeth, England.
Products and positioning
A diversified Indian business group combining regulated financial services, global pharmaceutical and healthcare capabilities, real-estate development and institutional philanthropy. Its current corporate structure emphasizes Piramal Finance as the principal listed lending platform and Piramal Pharma as a separately listed healthcare and life-sciences company.
Financial services
Piramal Finance
Piramal Finance is the group’s principal listed financial-services platform following the 2025 merger of Piramal Enterprises into Piramal Finance. It operates in retail lending, housing finance, vehicle financing, corporate lending and real-estate finance. Its retail activities include lending delivered through partnerships with fintech and mobility platforms, while its institutional activities include corporate finance and distressed-asset investment managed through related alternatives businesses.
Pharmaceutical contract development and manufacturing
Piramal Pharma Solutions
Piramal Pharma Solutions is the group’s contract development and manufacturing organization. It supports pharmaceutical and life-sciences companies with development and manufacturing capabilities. The business forms part of Piramal Pharma Limited, the separately listed pharmaceutical company created through the 2022 demerger.
Hospital pharmaceuticals
Piramal Critical Care
Piramal Critical Care manufactures hospital-oriented pharmaceutical products, including inhalational anesthetics and other generic medicines. It is one of the principal operating divisions of Piramal Pharma Limited and represents the group’s focus on specialized products used in clinical and acute-care settings.
Consumer healthcare
Piramal Consumer Products Division
The Piramal Consumer Products Division markets over-the-counter healthcare products. It forms part of Piramal Pharma Limited and extends the group’s pharmaceutical capabilities into consumer-facing remedies and healthcare brands.
Real estate
Piramal Realty
Piramal Realty is the group’s wholly owned real-estate venture. It develops residential, commercial and mixed-use property projects and has described plans to develop approximately 30 million square feet through land acquired from its own sources. The group has also developed the Cross Roads mall in South Mumbai.
Bio-orthopaedic product · 2012
BST-CarGel
BST-CarGel is a bio-orthopaedic product associated with Piramal’s healthcare portfolio. The product received a European CE mark in 2012, marking a regulatory milestone for the group’s medical-product activities.
Radiopharmaceutical · 2013
NeuraCeq
NeuraCeq is a radiopharmaceutical associated with Piramal’s healthcare business. In 2013, the European Medicines Agency’s Committee for Medicinal Products for Human Use issued a positive recommendation for the product.
Philanthropy and social impact · 2006
Piramal Foundation
Established in 2006, the Piramal Foundation is the group’s philanthropic platform. Its initiatives have included health-information services such as Piramal Swasthya, solar-powered water access through Sarvajal, rural employment through Source for Change, education initiatives, leadership development and the Piramal Prize.
Marketing campaigns
- 2006Piramal Foundation social-impact programs
India
The Piramal Foundation developed programs addressing public health, clean water, education, rural livelihoods and institutional leadership. Named initiatives include Piramal Swasthya, Sarvajal, Source for Change, Pratham-related education work, the Piramal Foundation for Education Leadership and the Piramal Prize.
Outcome. The initiatives established philanthropy and social innovation as a continuing component of the Piramal Group’s identity.
Brand decisions
2025
Reverse merger of Piramal Enterprises into Piramal FinanceM&ABackground
Reserve Bank of India rules required upper-layer non-banking financial companies to be publicly listed by September 2025.
Action taken
Piramal Enterprises merged into its subsidiary Piramal Finance Limited, which became the group’s primary listed financial-services arm.
Aftermath
The combined entity focused on retail and wholesale lending and began trading under PIRAMALFIN on 7 November 2025.
2022
Demerger and separate listing of Piramal PharmaStrategyBackground
Piramal separated its pharmaceutical and life-sciences operations from the broader Piramal Enterprises structure.
Action taken
The pharmaceutical division was demerged into Piramal Pharma Limited and separately listed.
Aftermath
The restructuring gave the pharmaceutical business a dedicated listed corporate vehicle while leaving financial services as the principal focus of Piramal Enterprises.
2021
Acquisition of Dewan Housing Finance CorporationM&ABackground
Piramal Capital & Housing Finance pursued the resolution of Dewan Housing Finance Corporation through India’s Insolvency and Bankruptcy Code process.
Action taken
Piramal acquired DHFL for a reported ₹34,250 crore and combined the business with its housing-finance platform.
Aftermath
The acquisition expanded Piramal’s lending platform and was characterized as the first resolution of a financial-services company under the Indian insolvency code.
Reported acquisition consideration. ₹34,250 crore (2021)
2020
Divestment of glass-packaging businessM&ABackground
The group continued to concentrate its portfolio on financial services, pharmaceuticals and related healthcare activities.
Action taken
Piramal sold its glass-packaging business to The Blackstone Group.
Aftermath
The divestment removed one of the industrial businesses that had played a foundational role in the group’s diversification.
Reported transaction value. Approximately US$1 billion (2020)
2010
Sale of domestic formulations business to AbbottM&ABackground
Piramal sought to reshape its healthcare portfolio and redeploy capital toward other businesses.
Action taken
The group sold its domestic formulations business to Abbott Laboratories.
Aftermath
The transaction became a major turning point, supporting Piramal’s later expansion into financial services, analytics and specialty healthcare.
Reported transaction value. Approximately US$3.72 billion (2010)
Recent events
Piramal Group completes takeover of DHFL[2]
Reported:
Piramal Group concluded payment of Rs 34,250 crore to take over Dewan Housing and Finance (DHFL). The report says Piramal Capital and Housing Finance will merge with DHFL and the merged entity will be renamed PCHFL.
Piramal Alternatives appoints Kalpesh Kikani as CEO[3]
Reported:
Piramal Enterprises said it appointed Kalpesh Kikani as CEO of its Alternatives business. The source reports the announcement on Wednesday; the event date is the article’s publication date.
Weekdays and relative dates follow the original report; their exact calendar dates have not been verified.
Piramal Group pledges Rs 25 crore to PM CARES Fund[4]
Reported:
Piramal Group said it had pledged Rs 25 crore to the Prime Minister's Citizen Assistance and Relief in Emergency Situations Fund (PM CARES Fund) to fight the COVID-19 pandemic.
Sources4 sources
Cite this profile: Cite the canonical profile. /brand-wiki/piramal-group · Editorial policy · How profiles are compiled